AGM Shareholder Questions, page-24

I should have used more tempered language but I'm concerned that in a fit of anger we'll throw the baby out with the bathwater but you're quite right. There have been mistakes they could have avoided going back to the biggie, placing all the bets on the incompletely tested capsule which cost this company at least two years development time, possibly out of a desire to save costs, and more recently the failure to build up a backup stock of their own raw mpl to keep things moving forward, even if more slowly in case the deal with Elanco fell through, as it did,, although I want people to realise just how hard mTOR medication development has actually proven in the wider world. And then there's been the issue of publicity and false hopes. Anyway, they're on notice to start delivering.